证券代码：300841 证券简称：康华生物 公告编号：2023- 出席本次说明会的人员有：公司董事长、总裁王振滔先生，副总裁、财务负 责人吴文年先生，副总裁、董事会秘书陆皓先生，独立董事方小波先生，保荐代 表人陈耀先生（如有特殊情况，参与人员可能进行调整）。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月 13日（星期四）14:00前访问http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征 集专题页面，公司将在2022年度业绩说明会上，对投资者普遍关注的问题进行回 答。 欢迎广大投资者积极参与本次网上说明会。 （问题征集专题页面二维码） 029 成都康华生物制品股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚 假记载、误导性陈述或重大遗漏。 成都康华生物制品股份有限公司（以下简称"公司"）《2022年年度报告》 及其摘要已于2023年3月30日在中国证券监督管理委员会指定的创业板信息披露 网站巨潮资讯网（http://w ...

Group 1: Company Performance - In 2022, the company achieved a revenue of 1,446.72 million CNY, representing a year-on-year growth of 11.94% [3] - The net profit attributable to shareholders was 545.13 million CNY, a decrease of 1.83% compared to the previous year [3] - The company issued 8.10 million doses of freeze-dried human rabies vaccine, an increase of 68.84% year-on-year, with a 100% pass rate [3] Group 2: Research and Development - R&D investment in 2022 was 179.94 million CNY, a significant increase of 128.13%, accounting for 12.44% of total revenue [4] - The company has established multiple innovative vaccine platforms, including mRNA and recombinant protein VLP vaccine platforms [5] - The six-valent norovirus vaccine has received approval for Phase I clinical trials in Australia [5] Group 3: Market Strategy and Sales - In 2022, the company sold 5.31 million doses of vaccines, supported by enhanced professional sales capabilities and digital marketing strategies [7] - The company plans to strengthen brand building and increase market coverage in 2023 [7] - The strategic focus includes maintaining leadership in the human diploid rabies vaccine market while advancing innovative vaccine projects [8] Group 4: Challenges and Future Outlook - The decrease in net profit was primarily due to reduced fair value gains from associates and increased R&D expenditures [4] - The six-valent norovirus vaccine addresses unmet clinical needs, presenting significant market potential [6] - The company aims to provide high-quality vaccine products to meet urgent clinical demands and contribute to public health [8]

Financial Performance - Chengdu Kanghua Biological Products Co., Ltd. reported a cash dividend of 5 RMB per 10 shares for all shareholders, with no bonus shares issued[5]. - The company's operating revenue for 2022 was CNY 1,446,724,761.50, an increase of 11.94% compared to CNY 1,292,447,990.55 in 2021[24]. - The net profit attributable to shareholders decreased by 27.90% to CNY 598,066,216.17 from CNY 829,477,810.74 in the previous year[24]. - The net cash flow from operating activities increased by 49.62% to CNY 194,990,553.03, up from CNY 130,325,659.99 in 2021[24]. - The total assets at the end of 2022 reached CNY 3,711,065,217.69, representing a 22.96% increase from CNY 3,018,041,385.96 at the end of 2021[24]. - The basic earnings per share decreased by 27.56% to CNY 4.4652 from CNY 6.1638 in 2021[24]. - The company recorded a total of CNY 52,932,528.92 in non-recurring gains and losses for 2022, down from CNY 274,187,334.45 in 2021[29]. - The company's total equity attributable to shareholders increased by 15.18% to CNY 3,075,667,953.11 at the end of 2022[24]. - The company achieved operating revenue of 1,446.72 million yuan, a year-on-year increase of 11.94%[39]. - The net profit attributable to the parent company was 598.07 million yuan, a year-on-year decrease of 27.90%[39]. - The gross profit margin for the main product, freeze-dried human rabies vaccine (human diploid cells), was 93.75% in 2022, with a year-on-year increase of 10.37%[57]. Research and Development - R&D investment reached 179.94 million yuan, an increase of 128.13% year-on-year[40]. - The company launched 9 R&D projects, with the six-valent norovirus vaccine obtaining Phase I clinical trial approval in Australia in February 2023[40]. - The company completed the upgrade of its R&D center, enhancing its R&D capabilities[43]. - The company has a dedicated R&D team of 117 members, including 8 PhDs, and has implemented a multi-faceted R&D incentive mechanism to boost innovation[50]. - The company is currently developing a vaccine for multiple genotypes of norovirus, which is in the clinical research phase[65]. - The company has initiated clinical research for a meningococcal ACYW135 vaccine, aiming for market launch after completing preclinical studies[66]. - The total R&D investment for 2022 was ¥179,941,306.14, accounting for 12.44% of operating revenue[66]. - The company plans to launch several new vaccines, including a quadrivalent nasal spray flu vaccine and a rabies mRNA vaccine, which are currently in preclinical research[66]. Market and Industry Trends - The company operates in the rapidly growing vaccine manufacturing industry, which has seen significant support for new vaccine development globally[34]. - The global human vaccine market size grew from approximately $27.7 billion in 2017 to about $46 billion in 2021, with a compound annual growth rate (CAGR) of 13.5%[35]. - By 2025, the global human vaccine market is expected to reach approximately $83.1 billion and $131 billion by 2030[35]. - The domestic rabies vaccine market has seen major breakthroughs, including the introduction of Vero cell rabies vaccines and the launch of a human diploid cell rabies vaccine in 2014[36]. - Recent regulatory changes have strengthened vaccine circulation channels and supervision, including the implementation of the Vaccine Administration Law in December 2019[36]. - The "14th Five-Year" plan emphasizes the development of innovative vaccine products and the enhancement of vaccine supply systems[37]. - Major global players like Merck, GSK, Pfizer, and Sanofi Pasteur dominate the vaccine market, while Moderna and BioNTech are emerging as new leaders with mRNA technology[38]. - The domestic vaccine market is fragmented, with state-owned enterprises leading the immunization planning vaccine market and intense competition in non-immunization planning vaccines[38]. Corporate Governance - The company has established a comprehensive governance structure, including a board of directors and supervisory board, to oversee its operations[4]. - The board of directors consists of 7 members, including 3 independent directors, ensuring a diverse range of expertise[103]. - The company strictly adheres to corporate governance standards, ensuring compliance with laws and regulations, and has established a sound internal management and control system[102]. - The company ensures timely and accurate information disclosure, allowing all shareholders equal access to information[106]. - The company operates independently from its controlling shareholders in terms of assets, personnel, finance, and business operations[107]. - The company has a well-structured corporate governance framework, including a shareholder meeting, board of directors, and supervisory board, ensuring independent operational management[111]. - The company has implemented a performance evaluation and incentive mechanism for senior management, ensuring transparency and compliance with legal standards[104]. - The internal audit system is in place, with an audit committee responsible for overseeing internal and external audits[104]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[160]. - The company obtained a pollution discharge permit on July 26, 2020, valid for three years[160]. - The company reported no exceedance of pollutant discharge limits for chemical oxygen demand, ammonia nitrogen, and total phosphorus[161]. - The wastewater treatment facility employs advanced technologies, including ultraviolet light purification and activated carbon adsorption, to manage emissions[161]. - The company has established an emergency response plan for environmental incidents, filed with local authorities in April 2021[162]. - The company has invested approximately 3 million yuan in the construction of a wastewater treatment station, with a monthly operating cost of about 10,000 yuan[166]. - The company has upgraded its vaccine production capacity and replaced its boiler to reduce nitrogen emissions[166]. Employee Management and Development - The company has a long-term development philosophy that emphasizes a performance-based compensation system, linking employee income to corporate performance[143]. - The training program includes internal and external training, focusing on industry knowledge, management skills, and operational training to enhance employee capabilities[145]. - The company has established a training organization system to ensure effective implementation of employee training across all levels[144]. - The company has a total of 793 employees receiving compensation, including retirees[142]. - The company has implemented an employee stock ownership plan and a stock incentive plan for core talents, with a total of 25 core talents involved[151]. Strategic Initiatives and Future Outlook - The company plans to expand its market presence and is focusing on new product development to enhance its competitive edge in the industry[117]. - Chengdu Kanghua announced a strategic initiative to increase its investment in research and development, aiming for a budget allocation of 15% of total revenue for 2023[117]. - The company is also exploring potential mergers and acquisitions to accelerate growth and diversify its product offerings in the coming years[117]. - The management provided guidance for 2023, projecting a revenue growth rate of 25% based on current market trends and product pipeline[117]. - The company aims to increase its production capacity by 50% by the end of 2023 to meet rising demand[183]. - Chengdu Kanghua is committed to sustainability, with plans to reduce carbon emissions by 30% over the next five years[184].

成都康华生物制品股份有限公司 投资者关系活动记录表 股票简称：康华生物 证券代码：300841 编号：2020-006 | --- | --- | --- | --- | |------------------------|----------------------------|--------------|-------| | | | | | | | ■ 特定对象调研 □分析师会议 | | | | | □ 媒体采访 □业绩说明会 | | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 □其他 | | | | | 1 、中泰证券 江琦 | | | | | 2 、东方自营 李峰 | | | | | 3 、中融基金 柯海东 | | | | | | | | | | 4 、南土资产 许智涵 | | | | 参与人员姓名及单位名称 | 5 、国寿安保基金 刘志军 | | | | | 6 、太平资产 周烨 | | | | | 7 、太平资产 闵东旭 | | | | | 8 、安信基金 池陈森 | | | | | 9 、华物投资 霍辰伊 | | | | 时间 | 2020 年 ...

成都康华生物制品股份有限公司 投资者关系活动记录表 股票简称：康华生物 证券代码：300841 编号：2020-008 | --- | --- | --- | |------------------------|------------------------|----------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 □其他 | | | | 1 、博颐投资 徐大成 | | | 参与人员姓名及单位名称 | 2 、博颐投资 雷雨 | | | | | | | 时间 | 2020 年 9 月 4 | 日（星期五） 11:00-12:00 | | 地点 | 陆家嘴东路 | 161 号招商局大厦 3115 室 | | 公司接待人员姓名 | | 副总经理、董事会秘书兼财务总监：唐名太 | | 投资者关系活动主要内容 | | | | 介绍 | 详见会议纪要 | | 日期 2020 年 9 月 4 日（星期五） ...

成都康华生物制品股份有限公司 投资者关系活动记录表 股票简称：康华生物 证券代码：300841 编号：2020-007 | --- | --- | --- | |------------------------|------------------------|----------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活动类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 □其他 | | | | 1 | 、平安医药 李刚平 | | | 2 | 、平安医药 陶歆蔚 | | | 3 | 、平安医药 倪亦道 | | 参与人员姓名及单位名称 | | | | 时间 | 2020 年 9 月 4 | 日（星期五） 9:00-10:00 | | 地点 | | 上海平安金融大厦会议室 | | 公司接待人员姓名 | | 副总经理、董事会秘书兼财务总监：唐名太 | | 投资者关系活动主要内容 | 详见会议纪要 | | 介绍 日期 2020 年 9 月 4 日（星期五） ...

成都康华生物制品股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------------|--------------------------|---------------------------------|----------| | 股票简称：康华生物 证券代码： | 300841 | 编号： | 2020-005 | | | ■ | 特定对象调研 □分析师会议 | | | | □ 媒体采访 □业绩说明会 | | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 □其他 | | | | 参与人员姓名及单位名称 | 1 | 、中国人保资产管理有限公司 | 蔡春根 | | | 2 | 、大成基金管理有限公司 陈丹霞 | | | | 3 、长盛基金管理有限公司 | | 代毅 | | | 4 | 、长盛基金管理有限公司 郝征 | | | | 5 | 、长盛基金管理有限公 张伟光 | | | | 6、 | Fenghe Asia F&H Fund Management | | | | 关雪 ...

成都康华生物制品股份有限公司 投资者关系活动记录表 股票简称：康华生物 证券代码：300841 编号：2020-001 | --- | --- | --- | |------------------------|-------------------------|----------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ 媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | | 1 、鹏华基金 冀洪涛 | | | | 2 、鹏华基金 李锐 | | | 参与人员姓名及单位名称 | 3 、鹏华基金 伍旋 | | | | 4 、鹏华基金 谢书英 | | | 时间 | 2020 年 6 月 24 | 日（星期三） 9:00 | | | | 成都康华生物制品股份有限公司二楼会议室 | | 地点 | （通讯方式） | | | | 董事、总经理：王清瀚 | | | 公司接待人员姓名 | | 副总经理、董事会秘书兼财务总监：唐名太 | | | ...